American Society of Clinical Oncology

SHERPA: White

People

  1. Kris
    Kris
  2. Riely
    Riely
  3. Drilon
    Drilon
  4. Ladanyi
    Ladanyi
  5. Rudin
    Rudin
  6. Yu
    Yu
  7. Arcila
    Arcila
  8. Paik
    Paik
  9. Rusch
    Rusch
  10. Berger
    Berger

Groups

  1. Department of Medicine (759)
  2. Solid Tumor Oncology Division (759)
  3. Thoracic Oncology (759)
  4. GSK Faculty (212)
  5. Department of Pathology and Laboratory Medicine (183)
  6. Weinberg Fellows (149)
  7. Human Oncology and Pathogenesis Program (142)
  8. Epidemiology and Biostatistics (122)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (116)
  10. Tow Center for Developmental Oncology (TCDO) (104)
Search Within
  1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (565)
  2. Journal Article (170)
  3. Guidelines (10)
  4. Review (7)
  5. Editorial (5)
  6. Correspondence (2)
Groups
  1. Department of Medicine (759)
  2. Solid Tumor Oncology Division (759)
  3. Thoracic Oncology (759)
  4. GSK Faculty (212)
  5. Department of Pathology and Laboratory Medicine (183)
  6. Weinberg Fellows (149)

More Groups

People
  1. Mark Kris (251)
  2. Gregory Riely (173)
  3. Alexander Drilon (161)
  4. Marc Ladanyi (96)
  5. Matthew Hellmann (96)
  6. Charles Rudin (92)

More People

Years
  1. 2025 (5)
  2. 2024 (69)
  3. 2023 (63)
  4. 2022 (66)
  5. 2021 (58)
  6. 2020 (57)

More Years

Publications
  1. Journal of Clinical Oncology (691)
  2. JCO Precision Oncology (42)
  3. American Society of Clinical Oncology Educational Book (11)
  4. Journal of Oncology Practice (10)
  5. JCO Clinical Cancer Informatics (5)

Results (759)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L) 1 therapy
    Meeting Abstract

    Gandhi, L.; Janne, P. A.; Opyrchal, M.; Ramalingam, S. S.; Rybkin, I. I.; Hafez, N.; Raez, L. E.; Gabrilovich, D.; Wang, F.; Ordentlich, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Response and durability of anti-PD-(L) 1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression
    Meeting Abstract

    Gainor, J. F.; Rizvi, H.; Jimenez Aguilar, E.; Mooradian, M.; Lydon, C. A.; Anderson, D.; Tenet, M.; Sauter, J. L.; Mino-Kenudson, M.; Shaw, A. T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial
    Meeting Abstract

    Felip, E.; Horn, L.; Patel, J. D.; Sakai, H.; Scheele, J.; Bruns, R.; Paik, P. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Felip, E.; Hellmann, M. D.; Hui, R.; Carcereny, E.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)
    Meeting Abstract

    Drilon, A. E.; Ou, S. H. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V. W.; Kim, H.; Kim, T. M.; Ahn, M. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Doebele, R. C.; Riely, G. J.; Spira, A. I.; Horn, L.; Piotrowska, Z.; Costa, D. B.; Neal, J. W.; Zhang, S.; Reichmann, W.; Kerstein, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Emergency department (ED) presenting symptom clusters for chemotherapy patients
    Meeting Abstract

    Daly, R. M.; Nicholas, K.; Gorenshteyn, D.; Sokolowski, S.; Gazit, L.; Adams, L.; Matays, J.; Katzen, L. L.; Chiu, O. O.; Xiao, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study
    Meeting Abstract

    Carbone, D. P.; Morgensztern, D.; Le Moulec, S.; Santana-Davila, R.; Ready, N.; Hann, C. L.; Glisson, B. S.; Dowlati, A.; Rudin, C. M.; Lally, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227
    Meeting Abstract

    Borghaei, H.; Hellmann, M. D.; Paz-Ares, L. G.; Ramalingam, S. S.; Reck, M.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Brahmer, J. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Lorlatinib in patients (Pts) with previously treated ALK(+) advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety
    Meeting Abstract

    Besse, B.; Solomon, B. J.; Felip, E.; Bauer, T. M.; Ou, S. H. I.; Soo, R. A.; Camidge, D. R.; Chiari, R.; Gadgeel, S. M.; Riely, G. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save